Huberman LabPeptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver
CHAPTERS
- 0:00 – 8:40
Peptides 101, GLP‑1 Agonists, and the Landscape of Performance Medicine
Huberman introduces Dr. Craig Koniver and frames peptides as a middle ground between nutrition/supplements and full hormone replacement. They define peptides, outline the explosion in GLP‑1 agonist use (semaglutide, tirzepatide) from diabetes into weight loss, and discuss off‑label prescribing and the context of America’s chronic disease and obesity burden.
- •Peptides are chains of ≤40 amino acids; proteins are larger.
- •The body likely makes hundreds of thousands of peptides; only ~150 have been therapeutically explored.
- •GLP‑1 agonists were first approved for type 2 diabetes and only later embraced off‑label for weight loss.
- •The majority of prescriptions in the US are off‑label uses of already‑approved drugs.
- •Koniver’s philosophy: use safe tools that help people feel and perform better, accepting that lifestyle alone often isn’t enough for many patients.
- 8:40 – 29:30
GLP‑1 Microdosing: Weight Loss, Muscle Preservation, and Inflammation
They examine the polarized narratives around GLP‑1 agonists: miracle drugs vs. dependency traps. Koniver explains his microdosing approach with compounded tirzepatide, his rule of ≤2 pounds per week of loss to avoid muscle wasting, and the synergistic role of exercise and protein. They also review emerging observations about GLP‑1’s effects on inflammation and autoimmunity.
- •Conventional GLP‑1 protocols often produce rapid 10–15 lb losses in weeks, leading to facial fat loss, muscle loss, and later rebound.
- •Koniver uses compounded tirzepatide in microdoses, titrated slowly, to mitigate adverse effects.
- •Concurrent resistance training and adequate protein are non‑negotiable to preserve lean mass.
- •He observes reductions in inflammatory markers, including thyroid peroxidase antibodies in Hashimoto’s patients, raising the possibility of GLP‑1 mediated immune modulation.
- •Benefits may be direct (immune signaling), indirect (fat loss), and psychological (improved self‑image and engagement with health behaviors).
- 29:30 – 43:40
BPC‑157: Systemic Repair, FDA Ban, and PDA as a Successor
The conversation turns to BPC‑157, once a workhorse peptide in Koniver’s practice for systemic anti‑inflammation and tissue repair. He details its effects on joints, gut, and connective tissue, the rationale for subcutaneous rather than local injections, and the lack of notable side effects. They then cover the FDA’s October 2023 crackdown and Koniver’s move to PDA (Penta‑DCA arginate) as a near‑analog replacement.
- •BPC‑157 was used extensively for joint pain, soft tissue injuries, post‑viral syndromes, and general recovery, often at doses up to 5,000 mcg/day (5 days on/2 off).
- •Injecting subcutaneously in the abdomen provided systemic benefits, including for gut issues and distant joints, suggesting targeted tissue homing.
- •No significant side effects observed in thousands of patients; BPC was even combined with PRP/PRF for rapid orthopedic healing.
- •FDA reclassified many peptides, including BPC‑157, onto a “Category 2” list, preventing compounding pharmacies from making them.
- •PDA (Penta‑DCA arginate), a one‑amino‑acid variant of BPC, is now being used at 250–500 mcg/day subcutaneously (Mon–Fri) with very similar clinical responses so far.
- 43:40 – 59:30
Safety, Sourcing, and the Role of Compounding Pharmacies
Huberman raises serious concerns about gray‑market peptide vendors that label products “not for human use.” Koniver explains how compounding pharmacies differ—from regulatory oversight to endotoxin testing—and why some patients have had life‑threatening reactions to research chemicals. They also distinguish compounded peptides and hormones from truly black‑market anabolic steroids.
- •Research‑chemical sites are not required to meet sterility or purity standards and frequently contain LPS/endotoxins.
- •Koniver has seen cases of anaphylaxis from such products; risks may be cumulative and unpredictable.
- •Compounding pharmacies are heavily regulated by the FDA and state boards and must validate sterility and purity via third‑party labs, especially for injectable products.
- •Working with a knowledgeable physician allows tailored dosing, stacking, and monitoring of labs and side effects.
- •The same logic applies to testosterone and other hormones: unsupervised early‑age use (teens, 20s) has led to azoospermia and long‑term HPT axis disruption in Koniver’s patients.
- 59:30 – 1:25:10
Growth Hormone Secretagogues: Sleep, Fat Loss, and Performance
They explore growth hormone biology and how peptide secretagogues can enhance endogenous GH pulses without exogenous hormone. Koniver contrasts ipamorelin, GHRP‑6, hexarelin, sermorelin, and tesamorelin, emphasizing goal‑specific selection and conservative dosing to avoid rare but real risks like anaphylaxis with overshooting.
- •GH release is pulsatile, with a major pulse between ~10 pm and 2 am; peptides aim to amplify that pattern, not override it.
- •Ipamorelin at 100 mcg pre‑bed (fasted ~45 minutes) is his cleanest option: modest GH increase, better sleep, some leaning effect, few side effects.
- •GHRP‑6 and MK‑677 strongly increase appetite and may raise prolactin/cortisol—helpful for hard‑gainers but poor choices for most seeking leanness or good sleep.
- •Hexarelin (100 mcg AM) can raise energy and endurance and is sometimes preferred for daytime performance.
- •Tesamorelin (2 mg) specifically targets visceral fat and was FDA‑approved for HIV‑related lipodystrophy; clinically, Koniver finds it often more potent in women.
- •CJC‑1295 was formerly combined with GH secretagogues to prolong GH/IGF‑1 activity but was also banned from compounding; semorelin and tesamorelin now often stand alone or in stacks.
- 1:25:10 – 1:48:00
Methylated B Vitamins, CoQ10, Methylene Blue, and Mitochondrial Support
They zoom out from peptides into foundational metabolic support, focusing on mitochondria. Koniver explains the electron transport chain in practical terms and how specific nutrients feed different complexes. He highlights CoQ10, methylated B vitamins for homocysteine control, and methylene blue as a cognitive and mitochondrial enhancer that also acts as a mild MAOI and antiviral.
- •CoQ10 (200 mg/day, sometimes much higher) supports Complex III and is safe up to ~2,400 mg/day in studies; Koniver sees strong benefits in migraine reduction.
- •Methylated B vitamins (methyl‑B12, methyl‑folate, methyl‑B6, TMG, methionine) help lower homocysteine and bypass common MTHFR polymorphisms.
- •Methylene blue, historically the first US pharmaceutical, binds Complex IV (cytochrome c oxidase), enhances electron transport, and is used for carbon monoxide poisoning.
- •At ~10 mg orally in the morning, methylene blue improves cognition and mood in many patients; doses given as liquid stain the mouth and turn urine green/blue.
- •Because it’s a mild MAOI, interactions with other serotonergic drugs must be considered; over‑the‑counter versions now exist but require careful sourcing and awareness.
- 1:48:00 – 2:17:20
Pinealon, Glycine, and Deep Sleep Architecture
Huberman shares his own striking experience with pinealon plus glycine: roughly doubling his REM sleep duration without sedation, with benefits that carry into non‑use nights. Koniver discusses pinealon as a pineal bioregulator, its pairing with glycine for inhibitory neurotransmission and liver detox, and how it compares to other sleep agents, including DORA‑class pharmaceuticals that failed for Huberman.
- •Pinealon is a micro‑peptide with strong effects on REM sleep and circadian rhythm; Koniver has not observed adverse effects in his patients.
- •Huberman experienced large, repeatable increases in REM sleep, measured via sleep tracking, and more stable sleep even on off nights.
- •Glycine, at 3–5 g orally (up to ≥10 g) before bed, calms the nervous system and supports phase II liver detox via amino acid conjugation.
- •Injectable glycine co‑administered with pinealon enhances the calming effect; pinealon is currently available as an injectable bioregulator peptide.
- •Koniver prefers injectable pinealon over oral bioregulator capsules, though some data suggest oral forms may survive gut digestion.
- •Cold plunges and intense exercise shift deep slow‑wave sleep; pinealon uniquely targets the REM component crucial for emotional processing and neuroplasticity.
- 2:17:20 – 2:47:20
NAD: IV Loading, SubQ Protocols, and Transformational Clinical Effects
They deep dive on NAD as a central mitochondrial and signaling molecule. Koniver recounts the history of NAD infusions in addiction treatment and his optimization of dosing to 750 mg infusions and a 5‑in‑10‑days loading protocol. He reports consistent, often dramatic improvements in mood, cognition, and energy, then explains monthly maintenance and subcutaneous alternatives for cost and access.
- •Original Mexican NAD addiction protocols used 3,000 mg/day IV for 10 consecutive days, taking 6–10 hours per infusion.
- •Koniver tested multiple doses and settled on 750 mg IV as a sweet spot: strong effects with tolerable infusion times (~1–2 hours in most patients).
- •Loading protocol: 5 infusions over 10 days; typical reports include elevated mood, sharper cognition, more vivid colors, better sleep efficiency, and resilience.
- •Maintenance: ~750 mg IV monthly, with some patients adjusting frequency; others use 100 mg subcutaneous NAD (5 days on, 2 off) as a practical alternative.
- •Huberman’s anecdote: a 750 mg NAD infusion during COVID coincided with rapid symptom improvement and test negativity the next day, suggesting powerful effects on systemic physiology.
- •For budget‑constrained individuals, Koniver recommends sublingual NMN as the first‑line oral option, with NR as another route supported by some human anti‑inflammatory data.
- 2:47:20 – 3:05:10
FDA Crackdowns, Pharma Incentives, and Patient Self‑Advocacy
Huberman presses Koniver on the recent FDA bans of many peptides and the possibility of pharma repackaging them into expensive drugs. Koniver believes there is both legitimate safety/regulatory concern and significant financial incentive. They argue that while pharmaceuticals are lifesaving in acute care, the chronic disease system is failing, and individuals must become informed advocates rather than passive recipients.
- •FDA placed numerous peptides (BPC‑157, CJC‑1295, thymosin alpha‑1, MK‑677, Epitalon, etc.) on lists that forbid compounding, even as pharma develops branded analogues like Vyleesi or GLP‑1 pens.
- •Koniver sees government overreach combined with pharma greed: the same molecules or close relatives will likely return as branded drugs at high prices.
- •He stresses that conventional medicine excels in emergencies (e.g., his own near‑fatal portal vein clot treated with anticoagulants), but underperforms in preventing and reversing chronic illnesses.
- •The 1910s Flexner Report cemented a pharma‑centric curriculum and marginalized nutrition, chiropractic, acupuncture, and other modalities.
- •Patients now often trust trainers, podcasters, and alternative clinicians more than primary care for practical health guidance, underscoring the trust gap.
- •Koniver advocates for skepticism, research, and partnership with trustworthy clinicians who are willing to combine evidence, clinical experience, and patient preferences.
- 3:05:10
Mindset, Time With Patients, and Positivity as a Health Multiplier
In closing, they set molecules aside and address the human element. Koniver describes leaving insurance‑based seven‑minute visits to build a practice that focuses on helping patients feel better fast, build trust, and then work on deeper behavioral and mindset changes. He argues that no good ever comes from negative thinking and that choosing positive interpretations and purposes is the most scalable and enduring health strategy.
- •Koniver dropped insurance in 2010 to escape 5–7 minute visits and instead spend meaningful time understanding patients’ lives and goals.
- •He sees IVs, peptides, and NAD primarily as tools to quickly relieve suffering so that patients gain the energy and hope to do the harder work of change.
- •In his view, positivity can never be “overdosed”; it shapes physiology and behavior in ways far greater than any single intervention.
- •We cannot choose our genetics or early environment, but we can choose our response and mindset, which in turn influence our biology and relationships.
- •COVID eroded trust in institutions but also put personal health front and center, driving people toward trustworthy long‑form education like Huberman’s work.
- •Koniver believes the combination of sound science, practical tools, and deliberate optimism is what ultimately allows people to find and live their purpose.
